Successfully reported this slideshow.
Your SlideShare is downloading. ×

Kshivets barcelona2020

Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad

Check these out next

1 of 1 Ad

More Related Content

Slideshows for you (20)

Similar to Kshivets barcelona2020 (20)

Advertisement

Recently uploaded (20)

Advertisement

Kshivets barcelona2020

  1. 1. Combined Gastrectomies: Survival Outcomes in Patients with Local Advanced Gastric Cancer Kshivets Oleg Surgery Department, Roshal Hospital, Roshal, Moscow, Russia P-15 OBJECTIVE: The survival of patients with local advanced gastric cancer (GC) takes several months. Radical operations are extremely complex and remain the prerogative of several best abdominal surgeons of the world. The search of optimal treatment plan for GC patients (GCP) with stage T3-4N0-2M0 was realized. We examined factors in terms of precise prediction of 5-year survival (5YS) of local advanced GCP after complete (R0) combined gastrectomies (G). METHODS: We analyzed data of 244 consecutive GCP (age=56.5±9.3 years; tumor size=7±3 cm) radically operated and monitored in 1975-2020 (m=182, f=62; total gastrectomy=75, distal gastrectomy=66, proximal gastrectomy=103, combined G with resection of 1-7 adjacent organs (pancreas, liver, diaphragm, colon transversum, splenectomy, small intestine, kidney, adrenal gland, etc.)=244; only surgery-S=166, adjuvant chemoimmunotherapy-AT=78: 5FU+thymalin/taktivin; T3=131, T4=113; N0=105, N1=37, N2=102, M0=244; G1=64, G2=54, G3=128. Multivariate Cox modeling, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine any significant dependence. RESULTS: Overall life span (LS) was 1617.1±1875.9 days and cumulative 5YS reached 48.8%, 10 years – 41.2%, 20 years – 33.7%. 73 GCP lived more than 5 years (LS=3870.8±2053.8 days), 32 – more than 10 years (LS=5589.5±2042.7 days). 106 GCP died because of GC (LS=615.4±347.6 days). AT significantly improved 5YS (63.5% vs. 44%) (P=0.004). Cox modeling displayed that 5YS significantly depended on: N0-N12, AT, blood cells, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), prothrombin index, protein, residual nitrogen, chlorides, blood group, Rh, (P=0.000-0.043). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), healthy cells/CC (2), erythrocytes/CC (3), thrombocytes/CC (4), lymphocytes/CC (5), stick neutrophils/CC (6), eosinophils/CC (7), segmented neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing. CONCLUSIONS: 5YS of local advanced GCP after combined radical procedures significantly depended on: tumor characteristics, blood cell circuit, cell ratio factors, biochemical factors, hemostasis system, anthropometric data, surgery type and adjuvant treatment. Optimal strategies for local advanced GCP are: 1) availability of very experienced abdominal surgeons because of complexity radical procedures; 2) aggressive en block surgery and adequate lymph node dissection for completeness; 3) precise prediction; 4) AT for GCP with unfavorable prognosis. Cox Proportional Hazards Results, GCP T3-4, n=244 Parameter Estimate Standard Error Chi-square P value 95% Lower CL 95% Upper CL Blood Group 0.314825 0.107017 8.65439 0.003263 0.10508 0.524574 Rh -0.571752 0.251562 5.16566 0.023038 -1.06480 -0.078700 Eosinophils 0.722557 0.222019 10.59166 0.001136 0.28741 1.157707 Stick Neutrophils 0.762058 0.230126 10.96594 0.000928 0.31102 1.213095 Segmented Neutrophils 0.747819 0.230098 10.56248 0.001154 0.29683 1.198804 Lymphocytes 0.756933 0.229396 10.88788 0.000968 0.30733 1.206542 Monocytes 0.794499 0.235432 11.38823 0.000739 0.33306 1.255937 Residual Nitrogen 0.047100 0.018290 6.63166 0.010018 0.01125 0.082948 Protein 0.024703 0.011467 4.64108 0.031215 0.00223 0.047178 Chlorides -0.043362 0.016420 6.97392 0.008271 -0.07555 -0.011180 Prothrombin Index 0.021356 0.008889 5.77267 0.016277 0.00393 0.038778 Adjuvant Chemoimmunotherapy -0.959072 0.302898 10.02557 0.001544 -1.55274 -0.365403 Erythrocytes tot 0.106408 0.029480 13.02814 0.000307 0.04863 0.164188 Leucocytes tot -0.029456 0.014556 4.09514 0.043007 -0.05799 -0.000927 Segmented Neutrophils/Cancer Cells 0.332251 0.145735 5.19761 0.022618 0.04662 0.617887 Healthy Cells/Cancer Cells -0.167621 0.051619 10.54476 0.001165 -0.26879 -0.066449 Phase Transition N0—N12 1.349169 0.228340 34.91149 0.000000 0.90163 1.796707 Neural Networks: Baseline Error=0.000; Area under ROC Curve=1.000; Correct Classification Rate=100%, n=179 Rank Sensitivity Phase Transition N0—N12 1 4771 Healthy Cells/Cancer Cells 2 4093 Erythrocytes/Cancer Cells 3 2400 Thrombocytes/Cancer Cells 4 2365 Lymphocytes/Cancer Cells 5 2200 Stick Neutrophils/Cancer Cells 6 1709 Eosinophils/Cancer Cells 7 1315 Segmented Neutrophils/Cancer Cells 8 1275 Leucocytes/Cancer Cells 9 1138 Monocytes/Cancer Cells 10 996 Bootstrap Simulation (Number of Samples=3333) Ran k Kendall Tau P Phase Transition N0---N12 1 -0.220 0.000 Blood Chlorides 2 0.171 0.01 Hemorrhage Time 3 -0.145 0.01 Tumor Growth 4 -0.118 0.05 T3-4 5 -0.114 0.05 Tumor Size 6 -0.108 0.05 Survival Function 5-Year Survival=48.8%; 10-Year Survival=41.2%; 20-Year Survival=33.7%; n=244; T3-4N0-2M0 Complete Censored -5 0 5 10 15 20 25 30 Years after Combined Gastrectomies 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 CumulativeProportionSurviving Cumulative Proportion Surviving (Kaplan-Meier) 5-Year Survival of GCP with N0=67.3%; 5-Year Survival of GCP with N1-2=34%; P=0.000 by Log-Rank Test Complete Censored 0 5 10 15 20 25 30 Years after Combined Gastrectomies -0.2 0.0 0.2 0.4 0.6 0.8 1.0 CumulativeProportionSurviving GCP with N1-2, n=139 GCP with N0, n=105 Cumulative Proportion Surviving (Kaplan-Meier) 5-Year Survival after Adjuvant Chemoimmunotherapy=63.5%; After Surgery=44%; P=0.004 by Log-Rank Test Complete Censored 0 5 10 15 20 25 30 Years after Combined Gastrectomies 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 CumulativeProportionSurviving Only Surgery, n=166 Adjuvant Chemoimmunotherapy, n=78 Cumulative Proportion Surviving (Kaplan-Meier) 5-Year Survival of GCP with Exophytic Growth=61.9%; 5-Year Survival of GCP wth Endophytic Growth=41.2%; P=0.001 by Log-Rank Test Complete Censored 0 5 10 15 20 25 30 Years after Combined Gastrectomies 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 CumulativeProportionSurviving Exophytic Growth, n=74 Endophytic Growth, n=163

×